Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Kumar S, Jagannath S, Weisel KC, Rosiñol L, Leleu X, Dimopoulos MA, Kastritis E, Siegel DS, Monge J, Du J, de la Rubia J, Asensi Cantó P, Lee JH, Mateos MV, Puertas B, Gozzetti A, Dytfeld D, Ocio EM, Blade J, Ozaki S, Beksac M, Escalante F, Nagaraj M, Hassan R, Bonar N, Spin P, Shokoohi M, Siddiqui M, Wang D, Hou K, West MED, Hampp C, Green J, Humblet O, Breskin A, Harnett J, Ge W, Sobel RE, Jalbert JJ, Kroog GS, Rodriguez Lorenc K, Ma Q, Durie BGM

Open source

DOI: 10.1038/s41408-026-01466-2
Published: 2026 Mar 25
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-026-01466-2,
  title = {Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.},
  author = {Kumar S and Jagannath S and Weisel KC and Rosiñol L and Leleu X and Dimopoulos MA and Kastritis E and Siegel DS and Monge J and Du J and de la Rubia J and Asensi Cantó P and Lee JH and Mateos MV and Puertas B and Gozzetti A and Dytfeld D and Ocio EM and Blade J and Ozaki S and Beksac M and Escalante F and Nagaraj M and Hassan R and Bonar N and Spin P and Shokoohi M and Siddiqui M and Wang D and Hou K and West MED and Hampp C and Green J and Humblet O and Breskin A and Harnett J and Ge W and Sobel RE and Jalbert JJ and Kroog GS and Rodriguez Lorenc K and Ma Q and Durie BGM},
  year = {2026},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-026-01466-2},
  url = {https://doi.org/10.1038/s41408-026-01466-2}
}

RIS

TY  - JOUR
TI  - Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
AU  - Kumar S
AU  - Jagannath S
AU  - Weisel KC
AU  - Rosiñol L
AU  - Leleu X
AU  - Dimopoulos MA
AU  - Kastritis E
AU  - Siegel DS
AU  - Monge J
AU  - Du J
AU  - de la Rubia J
AU  - Asensi Cantó P
AU  - Lee JH
AU  - Mateos MV
AU  - Puertas B
AU  - Gozzetti A
AU  - Dytfeld D
AU  - Ocio EM
AU  - Blade J
AU  - Ozaki S
AU  - Beksac M
AU  - Escalante F
AU  - Nagaraj M
AU  - Hassan R
AU  - Bonar N
AU  - Spin P
AU  - Shokoohi M
AU  - Siddiqui M
AU  - Wang D
AU  - Hou K
AU  - West MED
AU  - Hampp C
AU  - Green J
AU  - Humblet O
AU  - Breskin A
AU  - Harnett J
AU  - Ge W
AU  - Sobel RE
AU  - Jalbert JJ
AU  - Kroog GS
AU  - Rodriguez Lorenc K
AU  - Ma Q
AU  - Durie BGM
PY  - 2026
JO  - Blood cancer journal
DO  - 10.1038/s41408-026-01466-2
UR  - https://doi.org/10.1038/s41408-026-01466-2
ER  -

APA

S, K., S, J., KC, W., L, R., X, L., MA, D., E, K., DS, S., J, M., J, D., J, D. L. R., P, A. C., JH, L., MV, M., B, P., A, G., D, D., EM, O., J, B., S, O., M, B., F, E., M, N., R, H., N, B., P, S., M, S., M, S., D, W., K, H., MED, W., C, H., J, G., O, H., A, B., J, H., W, G., RE, S., JJ, J., GS, K., K, R. L., Q, M., & BGM, D. (2026). Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.. Blood cancer journal. https://doi.org/10.1038/s41408-026-01466-2

Source records

pubmed · retrieved 2026-09-26T03:02:25.910Z